Invesco Exchange-Traded Fund Trust II has recently filed its NPORT-P report, providing a detailed overview of its financial status as of August 31, 2026. This filing is crucial as it outlines the fund's total assets, liabilities, and net assets, which are essential metrics for investors and industry analysts.
The report reveals that Invesco's total assets stand at approximately $289 million, with net assets reported at around $284 million. The filing also indicates total liabilities of about $5.4 million. These figures are significant for understanding the fund's financial health and its ability to manage investor capital.
Background
Invesco Exchange-Traded Fund Trust II, identified by the Central Index Key (CIK) 0001378872, operates within the investment sector. The company has undergone name changes in the past, previously known as PowerShares Exchange-Traded Fund Trust II. The latest filing was submitted on October 30, 2026, and is part of a series of recent filings that include multiple NPORT-P submissions on the same day.
What the Filing Says
The NPORT-P filing specifically highlights the fund's total assets of $289,276,224.11 and net assets of $283,844,868.17. It also notes total liabilities of $5,431,355.94. These metrics are critical for investors assessing the fund's performance and stability.
Impact
This financial disclosure may affect various stakeholders, including current and potential investors, as well as competitors in the exchange-traded fund market. The details provided in the filing can influence investor decisions and market dynamics, particularly as other funds in the industry benchmark their performance against Invesco's results.
What's Next
The filing does not specify what actions or developments will follow this report. However, investors and analysts will likely keep a close watch on Invesco's future filings and performance metrics.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






